Tue, Mar. 24, 5:35 PM
Wed, Jan. 7, 8:50 AM
- Thinly-traded nano cap Galectin Therapeutics (NASDAQ:GALT) is up 49% premarket on robust volume in response to its report of results from a 30-patient Phase 1 study of GR-MD-02 in patients with nonalcoholic steatohepatitis (NASH).
- The principal objective of the trial was to assess the safety, tolerability and pharmacokinetics of GR-MD-02 but investigators also noted a potential therapeutic effect on fibrosis as measured by a serum biomarker (FibroTest) and liver stiffness (FibroScan). Patients in cohort 3 who received 8 mg/kg GR-MD-02 showed a statistically significant reduction in FibroTest score versus placebo in one of the cohorts.
- Fibrotest is a composite score of six blood tests that correlate to the extent of liver fibrosis.
- NASH represents the next big potential payoff for drug firms after HCV.
- Previously: Galectin NASH treatment meets primary endpoint in Phase 1 (Nov. 10, 2014)
- NASH-associated tickers: (NASDAQ:GILD) (NASDAQ:SHPG) (NASDAQ:LJPC) (NASDAQ:CNAT) (NASDAQ:ICPT) (NASDAQ:RPTP)
Aug. 8, 2014, 3:49 PM
- First the good news:
- Tekmira (TKMR +38.1%) on a massive 25M share turnover; Raptor Pharmaceuticals (RPTP +28.2%) on a 4x surge in volume; Clovis Oncology (CLVS +11.6%) on 50% higher volume; RadNet (RDNT +20.4%) on 2x higher volume and Relypsa (RLYP +15%) on 2x higher volume.
- Now the bad news:
- TearLab (TEAR -21.2%) on 4x higher volume; Masimo (MASI -10.6%) on 3x higher volume; Volcano (VOLC -19.9%) on a 12x surge in volume and Hanger (HGR -24.9%) on a 16x surge in volume.
Aug. 8, 2014, 12:47 PM
Jun. 20, 2014, 5:36 PM
Jun. 17, 2014, 5:35 PM
Mar. 14, 2014, 12:48 PM
Mar. 13, 2014, 5:42 PM
Feb. 20, 2014, 12:47 PM
Feb. 20, 2014, 11:28 AM
- "Procysbi should become an important alternative for treating patients with nephropathic cystinosis," writes analyst William Tanner reiterating his Outperform and $17 price target. "The pace of market uptake has somewhat debunked the notion that the cost of therapy would adversely position the drug vs. Cystagon."
- Today's "encouraging" data on RP103 for Huntington's Disease, may also include evidence the drug could be "effective for treating a broad range of conditions characterized by mitochondrial disorders and intracellular cystine accumulation."
- RPTP +13.4%
Feb. 20, 2014, 9:11 AM
Jan. 10, 2014, 9:13 AM| 8 Comments
Jan. 10, 2014, 8:54 AM
- Add Raptor Pharmaceuticals (RPTP) to the list of stocks benefiting from the rally in liver disease plays sparked Thursday by ICPT.
- The company — which is developing RP103 for NAFLD — saw its shares rise 6% yesterday, and early trading suggests today will be another positive session.
- RPTP +7.5% premarket
- See also: GALT, CNAT piggyback on ICPT NASH results
Sep. 27, 2013, 5:37 PM
Sep. 25, 2013, 9:37 AM
- Raptor Pharmaceuticals (RPTP) falls in early trading on the heels of an Oppenheimer downgrade.
- "We believe that the market is already pricing in Procysbi adoption by 80%+ patients in the US and EU at current valuation," analyst Boris Peaker says, removing his $11 price target.
- Oppenheimer also says success in Huntington's (RP103) is critical for RPTP — "we view [this] as very risky," Peaker notes.
- Another concern: Procysbi pricing in Europe as "reimbursement may be more challenging" than in the U.S. See: Procysbi gets EU marketing authorization.
Aug. 29, 2013, 9:56 AM
- Raptor Pharmaceutical (RPTP) drops 5.7% to $12.02 following a bearish piece on Seeking Alpha by Gravity Research, which has given the stock a price target of below $4 after initiating coverage.
- Gravity Research reckons that the most that Raptor can expect to generate from its flagship drug Procysbi, which the FDA recently approved for treating nephropathic cystinosis, is "less than $4/share even under ideal conditions"
- Gravity Research also "assigns zero value to Raptor's pipeline due to strong evidence that the fundamental theories behind its leading indications are flawed."
- Nephropathic cystinosis is a rare genetic disorder "that causes the amino acid cystine to accumulate in every cell of the body, leading to kidney problems and the loss of too much sugar, proteins, and salt through the urine." (Medscape)
RPTP vs. ETF Alternatives
Other News & PR